CLONAZEPAM ORALLY DISINTERGRATING Tablets — Class II drug recall D-237-2013
Terminated recall by Teva Pharmaceuticals USA, Inc., reported 2013-04-10, distributed in NC. Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result fo
| Recall number | D-237-2013 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc., Sellersville, PA, United States |
| Recall initiated | 2013-02-07 |
| Classified | 2013-04-01 |
| Reported by FDA | 2013-04-10 |
| Terminated | 2014-01-15 |
| Distributed | NC |
| Quantity | 3 boxes |
| NDC | 00555-0096-96 |
| Lot numbers | 05/14, 32900136A |
Product
CLONAZEPAM ORALLY DISINTERGRATING Tablets, USP, 0.5 mg, 60 tablets (10 blister cards of 6 tablets each), TEVA PHARMACEUTICALS USA, Sellersville PA 18960, NDC #0555-0096-96
Reason for recall
Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-237-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.